Abstract: Example portable grills having reversible steam tray assemblies are disclosed. An example portable grill includes a cookbox, a heating element, a water pan, and a steam tray. The heating element is located within the cookbox. The water pan is located within the cookbox above the heating element. The water pan includes a bottom wall. The steam tray is located within the water pan. The steam tray includes a horizontally-oriented support wall having a plurality of openings extending therethrough. The steam tray is configured to be reversibly positioned within the water pan in a first orientation and a second orientation. The support wall is spaced from the bottom wall by a first distance when the steam tray is positioned in the first orientation. The support wall is spaced from the bottom wall by a second distance greater than the first distance when the steam tray is positioned in the second orientation.

Abstract: The present disclosure relates to certain (2,S)-N-[(1,S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

Abstract: This document presents an apparatus for a flexible air filter media that can be configured for shipping and storage having one or more flexible inserts mounted to the filter media along one or more portions of the accordion folds of the air filter material. The current invention permits the air filter apparatus to fold along both X and Y axes, create a tri-fold, and bend in a manner that provides for a much smaller volume for shipping purposes. The invention also permits attaching the flexible material to the center of the filter media and also inserts which allow sections of the air filter media to be nested one into another to reduce both shipping and storage volume.

Abstract: This invention relates generally to compositions for making anellovectors and uses thereof. For instance, a method herein can comprise providing a nucleic acid construct that comprises a first Anellovirus genome encoding an exogenous effector and a second Anellovirus genome or fragment thereof, arranged in tandem. In some embodiments, the nucleic acid construct results in production of an anellovector comprising an Anellovirus genetic element encoding the exogenous effector, enclosed in a proteinaceous exterior.

Abstract: The present invention relates to the use of cannabidivarin (CBDV) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients diagnosed with Rett syndrome. In a further embodiment the types of seizures include focal motor seizures with impairment, focal non-motor seizures with impairment, generalised motor seizures, generalised non-motor seizures, unknown onset motor seizures, and non-motor seizures. Preferably the dose of CBDV is between 2.5 mg/kg/day to 10 mg/kg/day.

Abstract: Eye and hand tracking systems in head-mounted display (HMD) devices are arranged with lensless camera systems using optical masks as encoding elements that apply convolutions to optical images of body parts (e.g., eyes or hands) of HMD device users. The convolved body images are scrambled or coded representations that are captured by a sensor in the system, but are not human-recognizable. A machine learning system such as a neural network is configured to extract body features directly from the coded representation without performance of deconvolutions conventionally utilized to reconstruct the original body images in human-recognizable form. The extracted body features are utilized by the respective eye or hand tracking systems to output relevant tracking data for the user's eyes or hands which may be utilized by the HMD device to support various applications and user experiences. The lensless camera and machine learning system are jointly optimizable on an end-to-end basis.

Abstract: Phthalonitrile adhesive formulations are provided. Such an adhesive formulation may comprise an etherimide-phthalonitrile oligomer having formula wherein R1 is an unsubstituted or substituted aryl group or an unsubstituted or substituted cycloalkyl group; R2 is an unsubstituted or substituted aryl group and n has a value of from 1 to 30. Also provided are methods of making and using the adhesive formulations.

Abstract: An integrated milling and production device. The device includes a production housing, a connector, a motor, and a milling bit. The production housing has a central bore with at least one flapper valve pivotally disposed therein and an actuator. Upon completion of milling operations, the connector may be disengaged from the production housing. The production housing may be repositioned in the well. Activation of the actuator permanently opens the flapper valve to permit the flow of production up the production housing to the well surface. The actuator may be a piston.

Abstract: Systems, devices, and methods are described herein for providing a graphical user interface for configuring presentations of content and controlling distribution of content, for example, through in conjunction with a management system.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes related to brain injury. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients diagnosed with hypoxic ischaemic encephalopathy (HIE) or anoxia at birth. In a further embodiment the types of seizures include tonic, tonic-clonic, atonic, myoclonic, absence, focal seizures with impairment and spasms. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients with PURA gene mutation. In a further embodiment the types of seizures include tonic, atonic and focal seizures with secondary generalisation. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

Abstract: The present disclosure provides binding agents, such as antibodies, that specifically bind ILT3, including human ILT3, as well as compositions comprising the binding agents, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising the binding agents.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients diagnosed with PCDH19 Epilepsy. In a further embodiment the types of seizures include tonic-clonic seizures. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients with BRAF mutation. In a further embodiment the types of seizures include tonic-clonic seizures. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients diagnosed with GPHN mutation. In a further embodiment the types of seizures include tonic and tonic-clonic seizures. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients with gross chromosomal mutations including 15q11.2 deletion; 1p36 deletion; 22Q11 duplication; 9p21.1 deletion with autistic spectrum disorder; monosomy 16p13.3 and trisomy 2p25.3; chromosome 3q duplication; and trisomy 13. In a further embodiment the types of seizures include tonic, tonic-clonic, atonic, absence, focal seizures without impairment, focal seizures with impairment and focal seizures with secondary generalisation. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced inpatients with SYNGAP1 gene mutation. In a further embodiment the types of seizures include atonic and absence seizures. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.

Abstract: The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are experienced in patients diagnosed with Cortical Dysplasia and Cortical Brain Malformation. In a further embodiment the types of seizures include atonic, tonic, and focal without impairment seizures. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.